PATENT CLAIM ANALYSIS

Application Number: 16182189
Application Type: Utility
Filing Date: 2018-11
Publication Date: 2019-02
Patent Classification: ["435", "320100"]

Abstract:
Genetically modified compositions, such as non-viral vectors and T cells, for treating cancer are disclosed. Also disclosed are the methods of making and using the genetically modified compositions in treating cancer.

Claim (Index 2):
The mammalian cell of  claim 1 , further comprising a genomic disruption in a T Cell Receptor Alpha Constant (TRAC) or T Cell Receptor Beta Locus (TCRB) gene sequence or portion thereof.

Metadata:
- Claim Count in Document: 52.0
- Percentile: 98.0
- Lexical Diversity: 1.4
- Patent Class: 435.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['15224151', '15250514', '15818649', '14221074', '15964423']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.6499843298926637
- 35 USC 102 Novelty (BERT): 0.6214076877241824
- Combined Prediction Score: 0.6471266656758157
- Mean Citation Score: 415.59590800000007
- Max Citation Score: 638.6059
- Similarity Product: 436.0606597862065

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 0
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test